Connect with us


Factbox-Worldwide coronavirus cases cross 285.08 million, death toll at 5,776,003



More than 285.08 million people have been reported to be infected by the novel coronavirus globally and 5,776,003​ have died, according to a Reuters tally.

Infections have been reported in more than 210 countries and territories since the first cases were identified in China in December 2019.

Interactive graphic tracking global spread of coronavirus: open in an external browser.

Eikon users can click for a case tracker.

The following table lists the top 50 countries by the number of reported cases. A complete list is available with the above links.




United States 825,663 53,653,002 25.27

India 480,860 34,822,040 3.56

Brazil 618,870 22,263,834 29.54

United Kingdom 148,421 12,748,050 22.33

Russia 656,997 10,479,344 45.47

France 123,552 9,740,600 18.45

Turkey 82,163 9,438,502 9.98

Germany 111,706 7,123,893 13.47

Iran 131,572 6,192,698 16.08

Spain 89,331 6,133,057 19.09

Italy 137,247 5,981,428 22.71

Argentina 117,111 5,556,239 26.32

Colombia 129,866 5,138,603 26.16

Indonesia 144,088 4,262,540 5.38

Poland 96,416 4,094,607 25.39

Mexico 299,132 3,961,662 23.7

Ukraine 95,690 3,660,620 21.44

South Africa 91,061 3,446,532 15.76

Netherlands 20,892 3,116,039 12.12

Philippines 51,373 2,841,260 4.82

Malaysia 31,428 2,754,513 9.97

Czech Republic 35,975 2,469,925 33.84

Peru 202,584 2,287,494 62.09

Thailand 21,672 2,225,279 3.12

Canada 30,248 2,102,470 8.16

Iraq 24,154 2,093,436 6.28

Belgium 28,267 2,075,781 24.72

Romania 58,714 1,807,223 30.16

Chile 39,096 1,804,704 20.87

Japan 18,405 1,733,255 1.45

Vietnam 32,158 1,714,742 3.37

Bangladesh 28,070 1,585,027 1.74

Israel 8,243 1,376,256 9.28

Portugal 18,937 1,358,817 18.41

Sweden 15,310 1,314,784 15.05

Serbia 12,688 1,297,147 18.17

Pakistan 28,921 1,294,836 1.36

Switzerland 11,775 1,288,437 13.83

Austria 13,701 1,274,995 15.5

Hungary 39,061 1,249,694 39.96

Greece 20,708 1,170,293 19.3

Jordan 12,620 1,061,560 12.68

Kazakhstan 13,005 987,386 7.12

Cuba 8,322 965,571 7.34

Morocco 14,844 961,058 4.12

Georgia 13,707 930,544 36.78

Slovakia 16,598 838,738 30.47

Nepal 11,588 828,207 4.13

Denmark 3,256 783,702 5.62

Ireland 5,912 768,449 12.15

Source: Reuters tally based on statements from health ministries and government officials

Generated at 04:00.


Mexican president has cardiac catheterization, health said to be good



Mexican President Andres Manuel Lopez Obrador underwent a cardiac catheterization in hospital on Friday and was found to be in good health, the interior ministry said in a statement.

“In this procedure, the heart and the arteries of the president were found to be healthy and functioning appropriately,” the statement said.

Lopez Obrador, 68, who had a serious heart attack in 2013 and recently recovered from his second coronavirus infection, underwent the procedure as part of a check-up every six months that include lab tests, electrocardiograms, stress tests and CT scans, the government said.

The medical team said the latest results indicated the need for a cardiac catheterization, without providing further details on why they performed what they described as a 30-minute procedure.

The government said “no other type of intervention” was needed and that Lopez Obrador was in “perfect health.”

The procedure inserts a thin tube into a large blood vessel leading to the heart and can detect how well the heart is working.

Lopez Obrador said he had mild symptoms from both bouts of COVID-19. In the most recent case earlier this month, he went into isolation for a week before returning to public activities, including lengthy daily news conferences.

On his first day back, he praised honey, pain reliever paracetamol and VapoRub, a topical ointment popular in Mexico, for helping ease his symptoms.

(Reporting by Daina Beth Solomon, Dave Graham and Miguel Angel Gutierrez; Editing by William Mallard)

Continue Reading


Small children getting less sick from Omicron; Genetic mutation protects against severe COVID



The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

Small children are getting less sick from Omicron

In very young children, the Omicron variant of the coronavirus causes less severe disease than the Delta variant, according to a new study.

Researchers reviewed data on nearly 80,000 U.S. children under age 5 with a first infection, including 7,201 infected in late December or early January when Omicron was causing more than 90% of cases. After accounting for other risk factors, including medical conditions and socioeconomic circumstances, researchers found children infected during the Omicron surge had a 29% lower risk of emergency department visits, a 67% lower risk of hospitalization, a 68% lower risk of needing intensive care, and a 71% lower risk of needing machines to breathe, compared to children infected with Delta. However, “because of Omicron’s increased transmissibility, the overall number of emergency department visits, hospitalizations, ICU admissions, and mechanical ventilator use in children may still be greater” with Omicron than with Delta, according to a report posted on medRxiv ahead of peer review.

The investigators have also observed that infection rates were disproportionately higher in Black and Hispanic children for both Omicron and Delta for this age group, and the gap widened for infections with Omicron, said study leader Rong Xu of Case Western Reserve University School of Medicine. Not yet published data shows that “children under 5 had the highest infection rate with Omicron” compared to older children and adults in all age groups, she said.

Genetic mutation protects against severe COVID-19

New findings add to evidence that people with a certain version of a gene are less likely to develop severe COVID-19.

Earlier research had identified a specific group of genes, called the OAS1/2/3 gene cluster, as being involved in the risk for severe COVID-19. One version of a gene in that cluster – passed down from Neanderthals – appeared to protect against severe disease, reducing the risk by about 23%. The earlier research was done mainly in people of European ancestry. According to a report published in Nature Genetics, researchers now see the same association of this genetic variant with less severe COVID-19 in people of African ancestry.

“The fact that individuals of African descent had the same protection allowed us to identify the unique variant in the DNA that actually protects from COVID-19 infection,” coauthor Dr. Jennifer Huffman of said in a statement. OAS genes are involved in a cascade of effects that help cells fight viruses, the researchers said. Understanding of these genes and their effect on COVID-19 risks could aid development of future drugs, they added.

Fewer Delta breakthroughs with Moderna vs Pfizer/BioNTech

When the Delta variant of the coronavirus was prevalent in the United States, recipients of two doses of Moderna’s mRNA vaccine were less likely to experience a breakthrough infection – and if they did, were slightly less likely to be hospitalized – than recipients of two doses of the mRNA vaccine from Pfizer and BioNTech, a large study found.

Researchers analyzed health records of more than 637,000 vaccine recipients who were not previously infected with the virus and had not gotten a booster shot. As reported on Thursday in JAMA, breakthrough infections steadily increased every month from July to November 2021, with higher rates in the Pfizer/BioNTech group. In November, there were 2.8 cases among every thousand people vaccinated with the Pfizer/BioNTech shots, compared to 1.6 cases per thousand recipients of the Moderna vaccines. The vaccines protected equally well against death, but the hospitalization rate was 12.7% for infected Moderna recipients and 13.3% for Pfizer/BioNTech recipients. When the researchers compared 62,584 Moderna recipients to a closely-matched equal-sized group of Pfizer/BioNTech recipients, the risk for breakthrough infection was 15% lower in the Moderna group.

“Although there is a difference in breakthrough infections, both vaccines are highly protective against SARS-COV2 infection and especially against the most severe consequences of infection,” said coauthor Pamela Davis of Case Western Reserve University School of Medicine in a statement.

Click for a Reuters graphic on vaccines in development.


(Reporting by Nancy Lapid; Editing by Bill Berkrot)

Continue Reading


FDA expands use of remdesivir to patients with high risk of hospitalization



The U.S. health regulator on Friday expanded its approval for the use of Gilead Sciences’ antiviral drug remdesivir to treat non-hospitalized patients 12 years and older for the treatment of mild-to-moderate COVID-19 disease with high risk of hospitalization.

Previously, the use of Veklury was limited to patients requiring hospitalization.


(Reporting by Leroy Leo in Bengaluru; editing by Diane Craft)

Continue Reading